Enspryng Phase III results released by Roche (SIX: RO, ROG; OTCQX: RHHBY) signal a historic turning point for patients living with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD). The pivotal Phase III METEOROID study met its primary endpoint, demonstrating that satralizumab (Enspryng) significantly reduced the risk of relapses by 68% compared to placebo in adults and adolescents.
MOGAD is a rare, debilitating neuroinflammatory condition that causes the immune system to attack the protective myelin sheath around nerves. Until these findings, there were no FDA-approved treatments specifically indicated for MOGAD, leaving patients to rely on off-label therapies.
Unpacking the Enspryng Phase III Results
The Enspryng Phase III results from the METEOROID trial showcased high levels of efficacy across both primary and secondary objectives. The study included 188 participants who were randomized to receive either satralizumab or a placebo. Data indicated that 87% of patients treated with Enspryng remained relapse-free at the 48-week mark, compared to just 67% in the control group.
These Enspryng Phase III results underscore the critical role of IL-6 inhibition in managing MOGAD. We are encouraged by the 68% risk reduction, which could provide much-needed stability for patients who live in constant fear of their next attack.
Dr. Levi Garraway, Roche’s Chief Medical Officer
Learn More: Roche’s Gazyva/Gazyvaro Gets U.S. FDA Approval for Lupus Nephritis Treatment
Key Efficacy Metrics (METEOROID Study)
| Clinical Endpoint | Enspryng (Satralizumab) | Placebo | Statistical Significance |
| Relapse Risk Reduction | 68% Lower | Reference | p = 0.0025 |
| Relapse-Free at 48 Weeks | 87% | 67% | Significant |
| Annualized Relapse Rate (ARR) | 0.12 | 0.38 | p = 0.0030 |
| Risk of New MRI Lesions | 79% Reduction | Reference | p < 0.001 |
This news article summarizes the breakthrough results from the Phase III METEOROID trial for Roche’s Enspryng in the treatment of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD).
Novo Nordisk IT Security Incident: Unauthorized System Access Detected in Denmark
Novo Nordisk A/S has confirmed an IT security breach involving unauthorized access to limited internal systems and data exfiltration. Core operations remain unaffected. […]
Danaher Acquisition of Masimo Completed in $9.9B Diagnostics Mega-Deal
Danaher Corporation has finalized its acquisition of Masimo Corporation, establishing the pulse oximetry and patient monitoring provider as a stand-alone operating company within its Diagnostics […]
AstraZeneca Advances Oral GLP-1 RA Elecoglipron Asset into Phase III Programme Following Robust Phase IIb Results
AstraZeneca is advancing its investigational once-daily oral small-molecule GLP-1 receptor agonist, elecoglipron, into a broad Phase III programme after Phase IIb trials demonstrated up to […]
Safety Profile Observed in Enspryng Phase III Results
Safety is a paramount concern for long-term autoimmune management. The Enspryng Phase III results confirmed that the safety and tolerability profile of satralizumab in MOGAD is consistent with its established profile in Neuromyelitis Optica Spectrum Disorder (NMOSD). The most frequently reported adverse events were mild to moderate, primarily consisting of injection-related reactions and upper respiratory tract infections.
| Adverse Event | Enspryng (%) | Placebo (%) |
| Injection-Related Reactions | 16% | 12% |
| Nasopharyngitis | 11% | 10% |
| Headache | 9% | 8% |
| Arthralgia | 7% | 5% |
| Urinary Tract Infection | 6% | 6% |
Clinical Implications and Next Steps
Following the successful validation of the Enspryng Phase III results, Roche intends to submit the data to global regulatory authorities, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). If approved, Enspryng would become the first-ever therapy specifically indicated for MOGAD, addressing a massive unmet medical need.
